Table 1 Baseline patient characteristics and treatment received.
Total (N = 406) | ER < 1% (N = 364) | ER1–9% (N = 42) | p-value | |
|---|---|---|---|---|
Median age, years (range) | 54 (25–84) | 55 (25–84) | 51 (30–82) | 0.136 |
Histology | ||||
No special type | 365 (90%) | 324 (90%) | 41 (98%) | 0.154a |
Lobular | 17 (4%) | 16 (4%) | 1 (2%) | |
Apocrine | 8 (2%) | 8 (2%) | 0 | |
Metaplastic | 6 (1%) | 6 (2%) | 0 | |
Medullary | 5 (1%) | 5 (1%) | 0 | |
Clinical stage at diagnosis | ||||
I | 134 (33%) | 126 (39%) | 8 (19%) | 0.031 |
II | 212 (52%) | 188 (52%) | 24 (57%) | |
III | 59 (15%) | 49 (13%) | 10 (24%) | |
Histologic grade | ||||
G1–G2 | 47 (12%) | 43 (12%) | 4 (10%) | 0.803 |
G3 | 351 (88%) | 314 (88%) | 37 (90%) | |
Median Ki67 expression % (range) | 58 (1–90) | 56 (1–90) | 60 (5–90) | 0.170 |
Neoadjuvant chemotherapy | ||||
Yes | 165 (41%) | 141 (39%) | 24 (57%) | 0.033 |
No | 241 (59%) | 223 (61%) | 18 (43%) | |
Type of neoadjuvant chemotherapy | ||||
Anthracycline-taxane based | 101 (61%) | 85 (60%) | 16 (67%) | 0.714 |
Anthracycline-taxane-based plus platinum salts | 64 (39%) | 56 (40%) | 8 (33%) | |
Adjuvant chemotherapy | ||||
Yes | 274 (67%) | 251 (69%) | 23 (55%) | 0.092 |
No | 132 (33%) | 113 (31%) | 19 (45%) | |
Chemotherapy received (in neoadjuvant and/or adjuvant setting) | ||||
Anthracycline-taxane based | 211 (52%) | 185 (51%) | 26 (62%) | - |
Anthracycline-taxane-based plus platinum salts | 87 (21%) | 77 (21%) | 10 (24%) | |
Taxane based | 25 (6%) | 23 (6%) | 2 (5%) | |
Taxane-platinum based | 8 (2%) | 8 (2%) | 0 (0%) | |
Otherb | 75 (18%) | 71 (20%) | 4 (10%) | |
Adjuvant endocrine treatment | ||||
Yes | 19 (5%) | 13 (4%) | 6 (14%) | 0.002 |
No | 387 (95%) | 351 (96%) | 36 (86%) |
